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Resumo  
A Diabetes é uma doença metabólica crónica caracterizada por hiperglicemia provocada por 
deficiências na secreção e/ou ação da insulina, associada a várias complicações, agudas ou crónicas, 
que afetam a qualidade de vida destes doentes. Uma das complicações crónicas mais comuns na 
diabetes é a Neuropatia Diabética Dolorosa (NDD), sendo a quinta principal causa de dor crónica em 
todo o mundo. A NDD é caracterizada por hiperalgesia mecânica e alodinia tátil e é acompanhada 
por alterações funcionais e neuroquímicas no sistema nervoso periférico e central. Atualmente, não 
existe tratamento eficaz para esta condição, sendo que se baseiam na prevenção e manutenção dos 
sintomas além de poderem apresentar efeitos secundários. Sabe-se que a disfunção nociceptiva 
espinhal durante a NDD é uma consequência da perda de ácido γ-aminobutírico (GABA), 
responsável pela inibição da dor, que está associada a uma reversão no fluxo neuronal de cloreto, 
induzida pela diminuição do co-transportador iónico potássio-cloro do tipo 2 (KCC2). Ratos 
diabéticos induzidos por estreptozotocina (STZ), exibem uma diminuição significativa na expressão 
do KCC2 na medula espinhal levando a um aumento da concentração intracelular de cloreto e a uma 
reversão do papel do GABA, de inibitório para excitatório. A inibição seletiva do miR-92, utilizando 
um vetor lentiviral, evita a diminuição da expressão de KCC2 no hipocampo. Considerando o papel 
do miR-92 sobre a regulação da expressão do KCC2 e as deficiências relatadas com este co-
transportador na medula espinhal durante a diabetes, era importante avaliar se a inibição do miR-92 
em ratos STZ seria uma possível terapia no alívio da dor, e avaliar o papel do KCC2 e do GABA 
como possíveis mediadores dos efeitos dessa inibição. Neste estudo, mostrou-se que a inibição do 
miR-92 em ratos diabéticos com neuropatia dolorosa aumentou a expressão do KCC2 e reduziu a 
nocicepção mecânica desses animais, o que aponta para um papel chave do miR-92 e do KCC2 na 
dor nociceptiva espinhal durante a NDD. Além disso, foi possível mostrar, através de um estudo 
farmacológico, que os resultados acima mencionados realmente dependem do KCC2 e do GABA, 
corroborando estudos anteriores. Foram ainda feitos estudos preliminares in vitro, para avaliar se a 
inflamação poderia estar a interferir a expressão de miR-2 e KCC2 neuronal. Embora os resultados 
não sejam conclusivos, sugerem um papel da inflamação na expressão do KCC2. Concluindo, este 
projeto identificou um potencial alvo terapêutico para a reversão das alterações na 
transmissão nociceptiva inibitória espinhal detetadas durante a NDD. 
 
Palavras-Chave: microRNA-92, medula espinhal, neuropatia diabética dolorosa, nocicepção 
mecânica 
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Abstract  
Diabetes Mellitus (diabetes) is a disease characterized by hyperglycemia resulting from defects 
in insulin secretion and/or its action, associated with several acute and chronic complications that 
affects the life quality of the patients. One of the most common complications of diabetes is Painful 
Diabetic Neuropathy (PDN), being the fifth main cause of chronic pain worldwide and causing a 
very debilitating condition. PDN is characterized by mechanical hyperalgesia and tactile allodynia 
and is accompanied by functional and neurochemical changes at peripheral and central nervous 
system. Currently, there are no efficient treatments for this disease since they are based on symptoms’ 
prevention and management, and may present side effects. During PDN there is a loss of γ-
aminobutyric acid (GABA)-mediated pain inhibition which was shown to be due to a reversal in 
chloride neuronal flux induced by the downregulation in 𝐾+ 𝐶𝑙− cotransporter 2 (KCC2). STZ-
diabetic rats have been shown to exhibit a significant decrease in KCC2 expression at the spinal cord 
leading to an increase in chloride intracellular concentration and a reversal shift of GABA’s 
properties. Recently, selective inhibition of miR-92, using a mir-92 sponge lentiviral vector approach 
was shown to prevent the decrease in KCC2 hippocampal expression. In this context, considering 
the role of miR-92 on the regulation of KCC2 expression and the impairments reported in this co-
transporter in the spinal cord during diabetes, it is important to evaluate the possible pain-relieving 
therapeutic potential of silencing miR-92 in STZ-diabetic rats with PDN and to evaluate the role of 
KCC2 and GABA as possible mediators of the actions of silencing miR-92. In our study, it is shown 
that selective inhibition of miR-92 in STZ-diabetic rats with PDN, increases spinal cord KCC2 
expression and reduces mechanical nociception, pointing for a key role of miR-92 and KCC2 in 
spinal pain abnormal nociceptive processing during PDN. Besides, it was possible to show, through 
a pharmacological study, that the results abovementioned depend on KCC2 and GABA, 
corroborating previous studies on their involvement in PDN. Preliminary in vitro studies were also 
undertaken to evaluate if inflammation may interfere with miR-92 and KCC2 neuronal expression. 
Although these preliminary results are not conclusive, they suggest a role for inflammation on KCC2 
expression. In conclusion, this project has identified a potential therapeutic target for reversal of the 
excitatory changes in spinal nociceptive transmission occurring during PDN. 
 
Keywords: miRNA-92, mechanical nociception, Painful diabetic neuropathy, spinal cord 
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I. Introduction 
  
1. Diabetes Mellitus  
 
Diabetes Mellitus (diabetes) is a disease characterized by hyperglycemia resulting from defects 
in insulin secretion and/or its action. There are three main types of diabetes: type 1 diabetes, type 2 
diabetes and gestational diabetes. In type 1 diabetes, there is an absolute deficiency of insulin 
secretion, caused by an autoimmune destruction of pancreatic β-cells. Primary symptoms of 
hyperglycemia of type 1 diabetes include polyuria, polydipsia, weight loss, polyphagia and blurred 
vision. Commonly, this immune-mediated diabetes occurs in childhood and adolescence. Some 
forms of type 1 diabetes have unknown etiologies, namely idiopathic diabetes. In type 2 diabetes, the 
most prevalent type of diabetes (~90-95% of those with diabetes), the cause is, very often, a 
combination between resistance to insulin action and inadequate compensatory insulin secretory 
response. During the development of this type of diabetes, damage in tissues can occur without 
noticeable clinical symptoms for a long period before its detection. Obesity or an increase body fat 
distributed predominantly in the abdominal region are among the various possible causes of this type 
of diabetes, as well as stress and other illness, such as infection. Gestational diabetes mellitus (GDM) 
is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. 
However, this type of diabetes was controversial for many years, since its diagnosis could not be 
done accurately, being some cases of GDM preexisting undiagnosed type 2 diabetes (American 
Diabetes, 2014; Skyler, 2004). 
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2. Epidemiology of Diabetes 
 
Diabetes is the most common metabolic chronic disorder in nearly all countries and continues to 
increase. This year, the International Diabetes Federation published the numbers of diabetes 
prevalence for 2013 in global scale. In Europe, prevalence of diabetes in the population aged between 
20 and 79 years old was 7,9%, in Eastern Mediterranean and Middle-East was 9,7% and North 
America presented the largest number of 11, 4% (Guariguata et al., 2014). In Portugal, the estimated 
prevalence of diabetes in 2013 was 13%, more than 1 million of Portuguese population, and more 
1,3% than first study made of prevalence in 2009. More worryingly, the prevalence of diabetes is 
rising due to increased obesity, changes in diet, lifestyle, and population ageing (Diabetologia, 2014; 
Gardete‐Correia et al., 2010; Guariguata et al., 2014). 
 
3. Painful Diabetic Neuropathy: a Complication of Diabetes 
 
Diabetes involve several medical complications, some of them affecting with severity life quality 
of these patients. Complications can be divided in acute and chronic complications. Within acute 
complications, individuals with diabetes can lead with diabetic ketoacidosis, hyperglycemic 
hyperosmolar state, hypoglycemia and infections in different locations (respiratory system, 
genitourinary, gastrointestinal and liver, head, skin) (Lamster, 2014). Chronic or long-term 
complications of diabetes include microvascular and macrovascular complications. Severe 
retinopathy, nephropathy, peripheral and autonomic neuropathy, and diabetic foot are the most 
common microvascular complications. Into macrovascular complications there are the coronary 
heart disease, cerebrovascular and peripheral arterial disease (American Diabetes, 2014; Lamster, 
2014). 
Diabetic neuropathy (DN) is one of the most common chronic debilitating complications of 
diabetes, affecting more than 50% of diabetic individuals (Lamster, 2014; Tesfaye et al., 2010). On 
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the other hand diabetes is the leading cause of neuropathy, defined as damage to the nerves of the 
peripheral nervous system (Callaghan, Cheng, Stables, Smith, & Feldman, 2012). DN can be 
classified into four main classes based on symptoms and their location: (1) distal symmetric 
polyneuropathy (DSPN); (2) autonomic neuropathy; (3) proximal motor neuropathy; and (4) focal 
mononeuropathy and multifocal (Lamster, 2014). 
 
 Classifications of diabetic neuropathies: 
 
(1) Diabetic distal symmetric polyneuropathy, also called diabetic peripheral 
neuropathy, is the most common DN and can be found in both type 1 and type 2 
diabetes (Callaghan et al., 2012; Kazamel & Dyck, 2015). This form of DN 
affects up to 50% of the individuals with diabetes and is characterized by pain, 
paresthesia, hyperesthesia, deep aching, burning, and sensory loss (Kazamel & 
Dyck, 2015; Tesfaye & Selvarajah, 2012). DSPN affects the nerves of 
extremities such as feet and hands, but symptoms can progress proximally 
(Ahmad & Mittal; Kazamel & Dyck, 2015; Lamster, 2014). 
(2) Autonomic neuropathy affects autonomic nervous system that controls 
automatic actions from the organs. This type of neuropathy can cause 
dysfunction of cardiovascular, gastrointestinal, genitourinary, sudomotor and 
metabolic systems affecting body’s homeostasis (Lamster, 2014). 
(3) Proximal motor neuropathy or diabetic amyotrophy is the less common, and 
mostly affects older individuals with type 2 diabetes (Lamster, 2014). This kind 
of neuropathy can cause muscle weakness and affects specially the upper 
muscles of legs and hips (American Diabetes, 2009; Diseases, Digestive, & 
Kidney, 2015). 
(4) Focal neuropathy or mononeuropathy affects only one nerve unlike the above-
mentioned neuropathies and can occur in medial, ulnar, radial and common 
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peroneal nerves (Boulton et al., 2005; Dyck et al., 2011). Multiple 
mononeuropathies are namely multifocal and the entrapment or compression of 
the nerves are commonly the cause (Kazamel & Dyck, 2015). 
Of 50%-60% of diabetic patients who develop neuropathy, about 25%-30% develop painful 
symptoms, mainly associated with DSPN (Tesfaye, Boulton, & Dickenson, 2013). This very 
debilitating condition is called painful diabetic neuropathy (PDN) and makes this metabolic disease 
the fifth main cause of chronic pain (Tesfaye et al., 2010; Tesfaye & Selvarajah, 2012). PDN affects 
sensory, autonomic and motor neurons of the peripheral nervous system, thus covering all types of 
nerve fibers. This complication severely affects patients’ quality of life, especially in those that pain 
appears as a major complaint in patients with PDN, pain is the most prominent and most frequent 
reason for searching health care professionals. PDN is defined by the International Association for 
the Study of Pain (IASP) as the ‘pain arising as a direct consequence of abnormalities in the 
somatosensory system in people with diabetes’. Hyperalgesia (exacerbated pain to noxious 
stimulation) and allodynia (pain induced by innocuous stimuli) are frequently present. The symptoms 
often described by patients with PDN include: burning pain, ‘electrical shock’ type shooting pain 
down the legs, lancinating pain, uncomfortable tingling, pain caused by touching clothes (allodynia), 
discomfort on walking and sensitivity to temperature changes (Duby, Campbell, Setter, White, & 
Rasmussen, 2004; Shakeel, 2014; Tesfaye, Vileikyte, Rayman, Sindrup, Perkins, Baconja, Vinik, 
Boulton, et al., 2011). These symptoms are more severe at night and often interferes with normal 
sleep (Tesfaye et al., 2013). 
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3.1. Modulation of Pain 
 
As illustrated in Figure 1, the sensory experience begins in the peripheral terminals of primary 
afferent fibers which respond to a countless of stimuli and translate this information into the dorsal 
horn of the spinal cord, where terminals of these fibers end. In the peripheral nervous system, three 
main types of sensory fibers exist: Aβ-fibers, Aδ-fibers, and C-fibers. 
 
Figure 1 – Detection, at the primary afferents neurons, of different stimuli by 
nociceptive fibers. (Stahl, 2013) 
 
Each of these fibers corresponds to the axons of first-order sensory neurons and has different 
properties that allow them to respond and transmit different types of sensory information. Aβ-fibers 
are thicker and highly myelinated, allowing them to quickly conduct action potentials from their 
peripheral to central terminals. These fibers normally respond to light touch and are responsible to 
transmit tactile information. Aδ-fibers are thinner, lightly myelinated, and consequently slower 
conducting. They respond to both thermal and mechanical stimuli. C-fibers are the smallest and are 
unmyelinated, thus being the slowest conducting. They detect selectively nociceptive or ‘painful’ 
stimuli (D'Mello & Dickenson, 2008). From here, the sensory fibers can take two main nociceptive 
ascending pathways, the lemniscal or the spinothalamic (Stahl, 2013). In the lemniscal pathway, 
responsible for touch and proprioception, the Aβ- and Aδ-sensory fibers can connect their axons of 
first-order to the axons of second-order in the medulla (Stahl, 2013; Tavares, Lima, & Almeida, 
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2014). Then, the axon of second-order neuron crosses the midline and follows the pathway to the 
thalamus where it connects with the axon of third-order neuron. In the spinothalamic pathway, the 
transmitted information refers to pain, temperature and rough touch. In this pathway, the axons of 
the first-order neuron coming from Aδ- and C-fibers transmits their impulses to the axon of the 
second-order neuron in the dorsal horn of the spinal cord. The side of the spinal cord to which the 
first-order neuron enters corresponds to the side from where the impulse was transmitted. This neuron 
then crosses the spinal cord midline and follows the pathway connecting to the axon of third-order 
neuron in the thalamus. In both pathways, the third-order neuron sends its axon to the thalamus, 
which in turns projects to cortical areas such as the somatosensory, anterior cingulate and insular 
cortices that are required for the conscious perception of pain (Tavares et al., 2014). Descending 
modulation starts from this point, when the cortical areas modulate the experience of pain and send 
their stimuli responses. These outputs are then sent to the periaqueductal grey (PAG) that 
communicates with the rostral ventromedial medulla (RVM) which, in turn, sends descending 
inhibitory or facilitatory projections to the spinal cord (Ossipov, Dussor, & Porreca, 2010). 
Furthermore, there are also excitatory, glutamatergic, and inhibitory, GABAergic and glycinergic 
interneurons inside the spinal cord and these can increase or decrease the response of nociceptive 
specific cells influencing the output of the dorsal horn (D'Mello & Dickenson, 2008; Tesfaye et al., 
2013). 
In neuropathic pain, repeated noxious inputs on nociceptive specific cells induced changes that 
will emphasize peripheral and central sensitization, which may result in disruption of antinociceptive 
system and exacerbation of pronociceptive system. These changes can lead to increased responses to 
a stimulus that is normally painful—hyperalgesia, or to a pain response to a stimulus that does not 
normally provoke pain—allodynia (Almeida, Leite-Almeida, & Tavares, 2006; McMahon, 
Koltzenburg, Tracey, & Turk, 2013).  
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3.1.1. Pain Processing in the Spinal Cord  
 
Over the past two decades, research in understanding the pathophysiological neural 
changes resulting in neuropathic pain increased dramatically. Such changes include 
alterations in the (1) excitability or activation threshold of primary sensory neurons, (2) 
increases in descending facilitation or decreases in descending inhibition from the brain, and 
(3) increases in excitatory signaling or decreases in inhibitory signaling in the dorsal horn of 
the spinal cord (Taylor, 2009). 
Descending inhibition of spinal nociceptive processing from the RVM was early studied 
and was the main focus of investigation for a long time. However, Frank Porreca and Alan 
Randich (Porreca, Ossipov, & Gebhart, 2002), from the University of Iowa, established the 
presence of descending facilitation in spinal nociception, and later, with Mark Urban 
(Pogatzki, Urban, Brennan, & Gebhart, 2002), they established a role for the RVM in the 
maintenance of hyperalgesic states following peripheral tissue injury. Using chemical 
stimulation, it was demonstrated that low concentrations of glutamate facilitate nociceptive 
processing while higher concentrations inhibit it. GABA and glycine are the main inhibitory 
neurotransmitters used by inhibitory neurons in the spinal cord dorsal horn. In most neurons, 
both neurotransmitters inhibit neuronal activation by hyperpolarizing the cell membrane and 
by activation of a shunting conductance, which impairs propagation of excitatory 
postsynaptic potentials along the dendrites of neurons (Zeilhofer, 2008). 
 
3.1.1.1 Role of Potassium-Chloride Co-transporters 
 
It is known that fast synaptic transmission depends on ion fluxes, and its efficacy is 
maintained through balance of transmembrane ionic gradients (Chamma, Chevy, Poncer, & 
Lévi, 2012). Chloride homeostasis depends on two cation-chloride co-transporters: sodium-
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potassium-chloride co-transporter 1 (NKCC1) and the potassium-chloride co-transporter 2 
(KCC2). Their effectiveness is reflected in the control of inhibitory transmission and its 
proper functioning. The most important inhibitory neurotransmitters in the adult mammalian 
spinal cord, GABA and glycine, depend on the gradient between intracellular and 
extracellular chloride concentrations to perform their action. In 2009, A.Stil et al. studied 
NKCC1 and KCC2 during the development of rat embryos and discovered that maturation 
of chloride homeostasis is not completed at birth and, at the same time (Stil et al., 2009). 
Moreover, from embryo to adult, NKCC1 and KCC2 levels suffer variations. In early 
developmental, NKCC2 levels are high in contrast to KCC2 levels, making NKCC1 the main 
chloride-potassium co-transporter in the brain. In the adult stage, NKCC1 decreases and 
KCC2 increases, leading with a reduction in the influx of chloride and a shift on its gradient 
(Price, Cervero, & de Koninck, 2005; Rivera et al., 1999). 
Hereafter, we will focus our attention on KCC2, since it has been shown to have a major 
role in the nociceptive neurons of the superficial spinal dorsal horn in chronic pain (Coull et 
al., 2003; Mantyh & Hunt, 2004; W. Zhang, Liu, & Xu, 2008). Besides, studies analyzing 
the spinal cord of diabetic rats showed that KCC2 (but not NKCC1) is decreased in this 
condition (Jolivalt, Lee, Ramos, & Calcutt, 2008; Lee-Kubli & Calcutt, 2014), making KCC2 
more relevant for our studies. KCC2 is a secondary active transporter that uses the energy of 
the electrochemical 𝐾+ gradient to transport 𝐶𝑙− and this way controls the electrochemical 
gradient of chloride ions in neurons. An increase in KCC2 concentration correlates with a 
progressive hyperpolarization of GABA reflecting a reduction of 𝐶𝑙− concentration in 
mature neurons. An experiment using knockout animals for KCC2 gene, verified that in the 
absence of KCC2 expression spine morphogenesis is compromised in immature neurons. 
This defect on spine maturation is associated with a reduced number of functional excitatory 
synapses as detected by a decreased density of synaptic clusters of the glutamate receptor, 
the most important excitatory neurotransmitter. Indeed, it has been shown that the blockade 
or knockdown of the spinal KCC2 in normal rats significantly reduced nociceptive threshold, 
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confirming that the reported disruption of anion homeostasis in lamina I neurons was 
sufficient to cause neuropathic pain (Chamma et al., 2012). 
Of the two existing potassium-chloride co-transporters, only KCC2, has been associated 
with PDN (Jolivalt et al., 2008; Lee-Kubli & Calcutt, 2014; Morgado, Pereira-Terra, Cruz, 
& Tavares, 2011; Morgado, Pereira‐Terra, & Tavares, 2011; Morgado, Pinto-Ribeiro, & 
Tavares, 2008). All of these studies demonstrated that STZ-diabetic rats exhibit a significant 
decrease in KCC2 expression at the spinal cord and, due to this GABA presented excitatory 
actions, contributing to spinally-mediated hyperalgesia in diabetes. In particular, Morgado 
and colleagues (C. Morgado, P. Pereira-Terra, et al., 2011; C. Morgado, P. Pereira‐Terra, et 
al., 2011; Morgado et al., 2008) verified that normalization of KCC2 expression at the spinal 
cord of STZ-diabetic rats with PDN was shown to reduce spinal hyperactivity and to elicit 
anti-nociception, pointing for a key role of KCC2 in spinal pain abnormal nociceptive 
processing during PDN.  
 
3.1.1.2 KCC2 and GABA Connection 
 
GABA is the major inhibitory neurotransmitter involved in spinal pain modulation in the 
adult nervous system. However, it can also have an excitatory role during embryonic 
neuronal development and in pathological conditions, such as chronic pain and epilepsy 
(Cordero-Erausquin, Coull, Boudreau, Rolland, & De Koninck, 2005; Coull et al., 2003). 
Indeed, the activation of ionotropic post-synaptic GABA A receptors (GABAAR) was shown 
to have excitatory depolarizing effects in spinal nociceptive neurons in chronic pain, which 
was shown to be due to a reversal in chloride neuronal flux induced by the downregulation 
in KCC2. In normal conditions, low intracellular levels of chloride are observed and the 
activation of GABAAR induces the influx of chloride into the neuron that results in neuronal 
hyperpolarization and inhibition of spinal pain transmission (Coull et al., 2003). The opposite 
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occurs when chloride accumulates in the neuron, which was shown to occur when KCC2 
was down-regulated or malfunctioning (Coull et al., 2003; Rivera et al., 1999). In such cases, 
a shift in GABA role from hyperpolarization to depolarization (Balena, Acton, Koval, & 
Woodin, 2008; Cordero-Erausquin et al., 2005; Coull et al., 2003; Stil et al., 2009) was 
observed, promoting excitatory instead inhibitory neuronal effects (Figure 2) (Cordero-
Erausquin et al., 2005; Coull et al., 2003; Lavertu, Côté, & De Koninck, 2013; Stil et al., 
2009). 
 
Figure 2 – KCC2 function in normal and pathological conditions. Modified from 
http://www.painresearchforum.org. Credit: Sylvain Côté, Université Laval. 
 
4. Therapeutic Strategies for Painful Diabetic Neuropathy 
 
Until now, prevention and management of underlying diabetes is the major approach to inhibit 
the development of painful diabetic neuropathy. The most successful strategy for preventing 
neuropathy in patients with diabetes is an intensive control of hyperglycemia and lifestyle 
modifications, increasing physical activity and control of food intake (Skyler, 2004). In fact, there is 
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no real treatment for PDN but for the symptoms when prevention does not result, as pain relieved 
drugs, and even those are poorly effective in pain relief during diabetes (Peltier, Goutman, & 
Callaghan, 2014). Unfortunately, the majority of affected patients do not report pain symptoms until 
PDN is severe and, in most of the cases, an irreversible condition (Tesfaye et al., 2010). Currently, 
there are three types of drugs used to relieve the symptoms of PDN: antiepileptics, antidepressants 
and non-specific analgesics. However, these drugs have been demonstrated to have poor efficacy 
besides presenting serious side effects such as orthostasis, somnolence, vertigo, urinary retention and 
erectile dysfunction (Boulton et al., 2005; Peltier et al., 2014; Tesfaye, Vileikyte, Rayman, Sindrup, 
Perkins, Baconja, Vinik, & Boulton, 2011). 
It is, then, extremely important to develop strategies to early diagnose PDN and preventive 
approaches to avert the pain symptoms. (Duby et al., 2004; Skyler, 2004; Tesfaye et al., 2010). 
 
5. MicroRNAs as Potential Therapeutic Targets in Painful Diabetic 
Neuropathy 
 
5.1 MicroRNAs Definition 
 
The microRNAs (miRNAs) are a family of small RNAs with approximately 21 to 25 
nucleotides and can modulate, negatively, gene expression at the post-transcriptionally level. 
miRNAs are non-coding RNAs that are derived from larger precursors that form imperfect 
stem-loop structures. In animals, most miRNAs bind to the target-3′ UTR with imperfect 
complementarity and function as translational repressors. miRNAs modulate gene 
expression driving RNA-induced silencing complex (RISC) to the mRNA targets. It can be 
by: (1) inducing mRNA degradation or (2) inhibiting the translation of target mRNAs. Once 
incorporated into a cytoplasmic RISC, the miRNA will specify cleavage if the mRNA target 
has sufficient complementarity to the miRNA, or it will repress productive translation if the 
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mRNA does not have sufficient complementarity to be cleaved. The small RNAs remains 
intact after cleavage of the mRNA target and can guide the recognition and destruction of 
other targets (Bartel, 2004; He & Hannon, 2004; Ruberti, Barbato, & Cogoni, 2012). 
The target mRNAs are recognized depending on the complementarities between 
positions 2 to 8 from the 5′ of miRNA (the seed sequence), and an miRNA Responsive 
Element (MRE) usually located inside the mRNA 3′ untranslated region (3′ UTR). The 
knowledge of this mechanism may be applied to target miRNA expression: directly, by using 
oligonucleotides or virus based constructs, and indirectly, by using drugs to modulate 
miRNA expression at the transcriptional and/or processing level (Ruberti et al., 2012). 
 
5.2 MicroRNAs in Diabetes  
 
During recent years, there have been increasing studies suggesting that the development 
of diabetes can result from miRNAs-associated gene expression alterations in several tissues 
that are critical under diabetes condition (Guay, Roggli, Nesca, Jacovetti, & Regazzi, 2011; 
Lawrie, 2013; Shantikumar, Caporali, & Emanueli, 2012). More precisely, several miRNAs 
have been shown to be involved in pancreas and β-cells function, affecting insulin 
production, its secretion and action (Fernandez-Valverde, Taft, & Mattick, 2011). Several 
miRNAs have already been studied and found to play a role in the adjacent disorders of 
diabetes, such as obesity, nephropathy, retinopathy, neuropathy and cardiac disease 
(Fernandez-Valverde et al., 2011; Kato, Castro, & Natarajan, 2013; Lawrie, 2013; 
Shantikumar et al., 2012). 
Further to the association between miRNAs and diabetes, they have also been shown to 
relate to the central and peripheral sensitization and chronic pain disorders, such as 
inflammatory, neuropathic and visceral pain (Andersen, Duroux, & Gazerani, 2014; Kusuda 
et al., 2011). At the spinal cord level, there are studies using different animal models of 
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chronic neuropathic pain where up-regulation of few miRNAs is regarded (Brandenburger 
et al., 2012; Sakai & Suzuki, 2014)  
Considering the inhibitory role of miRNAs, and considering the possibility of 
constructing vectors that silence their actions in specific cells, it is clear that miRNAs may 
be regarded as potential therapeutic targets in chronic pain conditions such as PDN (Kress et 
al., 2013; Zhao et al., 2010). 
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II. Objectives 
 
Considering the role of microRNA-92 (miR-92) in the regulation of KCC2 expression and the 
impairments reported for this co-transporter in the spinal cord during PDN, it is important to evaluate 
if miR-92 has a role in PDN-associated KCC2 downregulation, inasmuch as it may represent a 
potential novel target for pain relief. 
This study aims at (1) investigating whether miR-92 plays a role in the regulation of spinal cord 
KCC2 expression in STZ-diabetic rats with PDN, (2) evaluating the pain-relieving therapeutic 
potential of silencing miR-92 in the spinal cord of STZ-diabetic rats with PDN, (3) assessing the 
effects of a KCC2 inhibitor and a GABAAR antagonist on the mechanical nociception of STZ-
diabetic rats after silencing of miR-92, (4) evaluating if inflammatory conditions may interfere with 
miR-92 and KCC2 neuronal expression. 
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III. Materials and Methods 
 
1. Animals 
 
Male Wistar rats were purchased from Charles River, France. Rats were initially housed at 
random in groups of four animals per cage, in a room with controlled environment (temperature, 22 
± 2ºC; humidity, 45-65%; 12-hour light/dark cycle), and received food and water ad libitum. All 
procedures were performed in accordance with the ethical guidelines of the European Community 
Council Directive 2010/63/EU, and of the International Association for the Study of Pain for 
experimental pain research in conscious animal (Zimmermann, 1983). 
 
2. Preparation of Type 1 Diabetes Animal Model 
 
In vivo experiments were performed in the well-established streptozotocin (STZ)-induced Wistar 
rat model of type 1 diabetes (Courteix, Eschalier, & Lavarenne, 1993; Lenzen, 2008; Szkudelski, 
2001). The STZ is a cytotoxic glucose analogue that selectively causes death of pancreatic β-cells, 
causing an abrupt loss of insulin secretion (Figure 3) (Lenzen, 2008; Szkudelski, 2001). 
 
Figure 3 – Mechanism of streptozotocin (STZ) action in the STZ-induced rat model of type 1 diabetes. 
 
Unraveling the role of microRNA-92 in Painful Diabetic Neuropathy 
16 
 
Briefly, type 1 diabetes was induced in male Wistar rats (280-300 g) by intraperitoneal (i.p.) 
injection of STZ (60 mg/g body weight, Sigma-Aldrich, Portugal) dissolved in 0,1 M citrate buffer 
(pH=4,5). Control animals (CTR) received equal volumes of vehicle solution. After three days, blood 
glucose concentration was measure in blood samples taken from the tail vein of STZ-injected rats 
using glucose oxidase-impregnated strip testing (Breeze®, Bayer, Portugal). STZ-injected rats 
presenting blood glucose concentration higher than 270 mg/dL were considered diabetic (Calcutt, 
2004) and included in the study. 
 
3. Behavioral Evaluation 
 
3.1 Mechanical Nociception 
 
Mechanical nociception was evaluated in STZ-diabetic rats by using the Randall-Selitto 
paw-pressure test (PPT) (Ugo-Basile, Comerio, VA, Italy) (Randall & Selitto, 1957). 
Animals were handled daily by the experimenter for 7 days prior to the beginning of the 
tests, for habituation purposes. For the PPT, ascending mechanical forces were applied to the 
dorsal surface of right hindpaw and the mechanical force (in grams) that induced hindpaw 
withdrawal was recorded. The paw withdrawal threshold (PWT) of each animal was 
calculated as the average of three consecutive measurements, taken at 2 min intervals. 
 
3.2 Locomotor Activity 
 
Locomotor activity levels were assessed by performing the open field test (OFT). Each 
rats was individually placed in the center of a black acrylic open field arena (45x45x45 cm) 
and filmed for 10 minutes (min). The total distance travelled (in cm) by each rat was 
quantified using the Smart software version 3.0 (Panlab Harvard Apparatus). 
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Figure 5 – Illustration of pLSyn vector construct. 5’LTR: long terminal repeat on 5’ end 
(initiation). Syn: synapsyn promotor. EGFP: enhanced green fluorescence protein. 3’LTR: 
long terminal repeat on 3’ end (3’ end formation of viral transcripts). 
 
4. Lentiviral Vectors Preparation 
 
All construction and preparation of miRNA sponge vectors were made at the Institute of Cell 
Biology and Neurobiology, National Research Council (Rome, Italy), as described elsewhere 
(Barbato et al., 2010). To produce lentiviral particles, a third generation lentiviral vector and three 
plasmids were used. Each plasmid construct expresses important gene for lentiviral production. The 
mixture of these four plasmids was transfected in Human Embryonic Kidney (HEK) 293T cells. 
HEK293T cells virus-containing-medium was harvested 60 hours after transfection filtered and 
concentrated by ultracentrifugation. The titers of the viral vectors were in the range of 1-3 ×  109 
TU/mL (TU: transducing units) (Dull et al., 1998; Vilardo, Barbato, Ciotti, Cogoni, & Ruberti, 2010). 
In order to inhibit miR-92, the sponge lentiviral vector, pLSyn-miR-92 sponge, contains four 
binding sites to sequester miR-92 (Figure 4). pLSyn vector without binding sites for miR-92 was 
used as control (Figure 5). Both lentivirus constructs contain the enhanced green fluorescent protein 
(EGFP) gene under the control of the synapsyn promoter that allows the expression only in neuronal 
cells (Barbato et al., 2010). The expression of EGFP allows the quantification of transfection and 
transcription of lentiviral particles transgenes. 
pLSyn-miR-92 Sponge vector 
 
 
 
pLSyn vector 
 
 
5’LTR Syn EGFP 3’LTR 
 
5’LTR Syn EGFP 3’LTR 
miR-92 binding sites  
Figure 4 – Illustration of pLSyn-miR-92 Sponge vector construct. 5’LTR: long terminal repeat on 
5’ end (initiation). Syn: synapsyn promotor. EGFP: enhanced green fluorescence protein. 3’LTR: long 
terminal repeat on 3’ end (3’ end formation of viral transcripts). 
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5. Intraspinal Lentiviral Inoculations 
 
 For all inoculation procedures, rats were firstly anaesthetized with an i.p. injection of a mixture 
of ketamine and medetomidine (5 mg/kg of ketamine and 1 mg/kg of medetomidine), and anesthesia 
was then maintained with isoflurane (1-1.5% in 60% oxygen/air mixture) (Figure 6A). A dorsal 
laminectomy of spinal vertebrae T13-L1 was performed (Figure 6B). The dura mater was slit and 
two pressure injections, of 1.5 𝜇𝐿 each, were bilaterally performed about 1 mm lateral to the dorsal 
vertebral artery and 0.5 mm in depth through spinal cord surface, using a 10 𝜇𝐿 Hamilton syringe 
coupled to a glass micropipette with a tip diameter of about 30-40 µm. Injections were performed 
slowly at 2-min intervals between each 0.1 𝜇𝐿 bolus, and a 10-min waiting period was allowed after 
total volume injection to avoid reflux. Afterwards, the incision was closed with suture and 
atipamezole hydrochloride (1 mg/kg) was administered by an intra-muscular injection in order to 
reverse anesthesia. Animals were monitored for 4-5 hours after surgery and treated orally with 
tramadol hydrochloride (10 mg/kg) during that period. Animals were housed one per cage to prevent 
wound damage. 
 
Figure 6 – Intraspinal lentiviral inoculation. (A) Stereotactic surgical apparatus adapted for intraspinal injection. (B) 
L4-L5 spinal cord segment. 
 
A B 
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6. Intrathecal Drug Administration 
 
Intrathecal administrations of a KCC2 specific inhibitor—[(dihydroindenyl)oxy] Alkanoic acid 
(DIOA), 30 µg (Sigma-Aldrich), a GABAAR antagonist—Bicuculline (BIC), 0.6 µg (Sigma-
Aldrich), or vehicle solution [saline + 10% DMSO (dymetil sulfoxide)] were performed as follows. 
Each administration was carried out at least 48h apart to assure a suitable washout of the previous 
injected drug. Intrathecal injections (30 µl) were performed with a 26-gauge needle coupled to a 100 
µl Hamilton syringe by spinal puncture of intervertebral space at L5-L6 or L6-S1 level (Figure 7) 
under volatile anesthesia (2.5-5% isoflurane in 100% oxygen). This methodology was adapted from 
Jolivalt et al. (Jolivalt et al., 2008). 
 
Figure 7 – Illustration of the intrathecal site of drug administration. Modified from 
http://paperheartrats.com/blog/ 
 
7.  Animals Culling and Spinal Cord Tissue Collection 
 
At the end of the in vivo experiments, rats were anesthetized with pentobarbital sodium (i.p. 50 
mg/g body weight) and then decapitated. The spinal cord segments L4-L5 were promptly dissected 
and stored at -80ºC until further analyses. 
Unraveling the role of microRNA-92 in Painful Diabetic Neuropathy 
20 
 
 
8. Primary Neuronal Cell Cultures 
 
All experiments using neuronal cultures were performed at the Institute of Cell Biology and 
Neurobiology, National Research Council (Rome, Italy). In order to evaluate the role of TNF-α and 
IL-1β in neuronal expression of KCC2 and miR-92, primary neuronal cultures were prepared from 
hippocampal and spinal cord neurons harvested from Wistar rat embryos on embryonic days 17-18 
(E17-18). The tissues were dissected in HEPES-buffered Hanks’ balanced salt solution (Gibco) and 
dissociated via trypsin/EDTA treatment. Cells were plated at 1 × 106 cells on 3.5-cm dishes pre-
coated with poly(D/L-lysine) and cultured in neurobasal medium supplemented with B-27 and 
glutaMAX (Gibco), which was changed every 3–4 days (Barbato et al., 2010). 
To evaluate the role of TNF-α and IL-1β in neuronal expression of KCC2 and miR-92, primary 
hippocampal and spinal neurons after 15 days in culture, were treated with 50 ng/mL rat TNF-α 
(Sigma-Aldrich) or 10 ng/mL rat IL-1β (Sigma-Aldrich). 24h after treatment, neurons were harvested 
and used for Western blotting and RT-PCR analyses. 
 
9. Western Blotting 
 
9.1 Primary Neuronal Cell Cultures 
 
Hippocampal and spinal cord neurons were scrapped and homogenized in lysis buffer 
(1% Triton X-100, 0,25% SDS, 1% Sodium Deoxycholate, 2mM EDTA, 1mM DTT). After 
several freeze/thaw cycles and centrifugation at 12000xg for 20 min at 4ºC, supernatants 
were incubated 30 min on ice. Total protein concentration was quantified by detergent 
compatible (DC) protein assay (BioRad, Italy) using Bovine Serum Albumin (BSA) as a 
standard. For this experiment, the membranes were blocked in 7% skim milk in TBS-T (Tris 
Unraveling the role of microRNA-92 in Painful Diabetic Neuropathy 
21 
 
buffered saline with 0,05% Tween) for 1 hour at room temperature and then incubated in 
primary antibody rabbit anti-KCC2 (1:1000) in TBS-T containing 7% skim milk for 24 hours 
at 4ºC. GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was used as internal control, 
the membrane was blocked in 5% skim milk in TBS-T for 1 hour at room temperature and 
then incubated in primary antibody mouse anti-GAPDH (1:6000) in TBS-T containing 2% 
of skim milk. The membranes were then carefully washed with TBS-T and incubated with 
secondary antibody conjugated to horseradish peroxidase (HRP). 
 
9.2 Spinal Cord Samples 
 
The expressions of KCC2 and enhanced green fluorescent protein (EGFP) in the spinal 
cords from rats inoculated with pLSyn and pLSyn-miR-92 sponge lentiviral particles were 
determined by Western blotting analysis. Freshly dissected spinal cord L4-L5 segments were 
homogenized with a tissue homogeniser in lysis buffer (MOPS 20mM; EGTA 2mM; EDTA 
5mM; 1% Triton X-100) containing proteases inhibitor (1:100, Sigma-Aldrich, St. Louis, 
MO) and phosphatase inhibitor cocktail 2 and 3 (1:100, Sigma- Aldrich, St. Louis, MO). The 
homogenates were incubated on ice for 20 min and then centrifuged for 20 min at 21100xg 
at 4ºC. The supernatants were collected and centrifuged again for 10 min at 21100xg at 4ºC. 
Total protein concentration in the final supernatants was quantified by the Bradford method 
using BSA (Nzytech, Portugal) as a standard. Protein samples (40 µg) were added to 4x 
sample buffer (240 mM Tris/HCl pH 6.8, 40% glycerol, 8% SDS, 0,04% bromophenol blue) 
containing 10% of β-mercaptoethanol and denatured at 100ºC for 5 min. The samples and 
molecular weight marker (Protein Marker VI-10-245, AppliChem, USA) were loaded on a 
8% polyacrylamide gel and subjected to Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) at 20 mV, followed by electroblotting to a nitrocellulose 
membrane at 30 mV overnight. The membranes blots were then washed twice with 
phosphate buffered saline (PBS) containing 25% Triton X-100—PBS-T— and immersed in 
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Ponceau S Red staining solution (0.2 % Ponceau, 3% trichloroacetic acid and 3% 
sulphosalicylic acid) for 5 min to confirm protein transfer. After gently washing with distilled 
water, blots were immediately photographed using the Chemidoc system (BioRad, Portugal). 
Blots were then abundantly washed with PBS-T and, immersed in a blocking solution 
containing 5% skim milk in PBS-T for 1 hour at room temperature. Following this, blots 
were incubated with the appropriate primary antibody—rabbit anti-KCC2 (1:2000) or rabbit 
anti-GFP (1:2000) in PBS-T containing 5% BSA— for 24 hours at 4 ºC. On the following 
day, blots were carefully washed in PBS-T and incubated with anti-rabbit secondary antibody 
conjugated to horseradish peroxidase (HRP) (1:10000, GE Healthcare, USA) in PBS-T with 
5% of skim milk for 1 hour. After washing with PBS-T, blots were incubated with Clarity 
Western ECL Substrate (BioRad, Portugal) for 5 min and immunoreactive bands were 
detected by Chemidoc system (BioRad, Portugal).  
α-tubulin was used as an internal loading control, being the blots incubated with an anti-
α-tubulin primary antibody raised in mouse (1:10000, Sigma-Aldrich, St. Louis, MO) 
followed by incubation in anti-mouse secondary antibody conjugated to HRP (1:10000,GE 
Healthcare, USA). Detection and quantification of α-tubulin immunoreactive bands were 
performed as described above. Western blotting analyses results for each sample were 
calculated as the densitometric units ratio between the protein of interest and α-tubulin, and 
presented in arbitrary units. 
 
10.  Real-Time PCR 
 
Total RNA was extracted from either spinal cord tissue L4-L5 segments or hippocampal and 
spinal cord primary culture neurons, using TRIzol (Invitrogen) reagent according to the 
manufacturer’s instructions. Then, RNA was treated with TURBO DNA-free kit (Ambion) to 
avoid any possibility of DNA contamination. RNA quantification was performed by 
spectrophotometric analysis using the NanoDrop 2000 (Thermo Scientific). 
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For miR-92 quantification, the extracts were reverse-transcribed using Taqman microRNA 
reverse transcription kit (Applied Biosystems), and amplified with FastStart Universal Probe 
Master (Roche) in a 7900HT Fast Real-Time PCR System (Applied Biosystems). Relative 
changes in gene expression were quantified using the comparative threshold method (Ct) after 
determining the Ct values for endogenous control U6 and target miR-92 in each sample set. The 
experiments were performed using triplicates for each sample.  
For KCC2 mRNA, cDNA was synthetized using SuperScript III Reverse Transcriptase 
(Invitrogen, Italy) and amplified with the SensiMixPlus SYBR Kit (BioLine, Italy). Rat TATA 
binding (TBP) and KCC2 were amplified using the oligonucleotides for Rattus norvegicus: 
(RNO): RNO-TBP-RW:CAATTCTGGGTTTGATCATTCTG; RNO-TBP-
FW:CCCACCGCAGTTCAGTAGC; RNO-KCC2-FW:CCTCTTTCTGCGGCTCACT; RNO-
KCC2-RW: GAAATGGCTGTGAGCATCG (Barbato et al., 2010; Vilardo et al., 2010). 
Relative changes in gene expression were quantified using the comparative threshold method 
described above. 
 
11.  Statistical Analysis 
 
GraphPad Prism version 6.0 was used for statistical analyses. The results from KCC2 mRNA 
and miR-92 expression levels were compared by independent sample t test. Blood glucose 
concentration and body weights of STZ rats were compared by independent sample t test. The PWTs 
from STZ rats treated with pLSyn and pLSyn-miR-92 sponge were compared by Two Way Analysis 
of Variance with repeated measures (ANOVA-RM) followed by Bonferroni post-hoc test for 
multiple comparison. The behavioral findings from the time-course pharmacological study 
performed in STZ-inoculated rats were compared by ANOVA-RM followed by Bonferroni post-hoc 
test for multiple comparisons. In this analysis, one STZ rat inoculated with pLSyn and receiving BIC 
was excluded from the statistical analysis because the execution of PPT was not performed at 15 min 
as the animal was still under anesthesia and without normal reflexes. The western blot results from 
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STZ-inoculated animals were compared by independent sample t test. Results from cell experiments 
were compared by One-Way ANOVA followed by Bonferroni post-hoc test for multiple 
comparisons. Results are presented as mean±SEM and statistical significance was settled at p<0.05. 
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IV. Results 
 
1. Study 1: Evaluation of the expression levels of KCC2 mRNA and miR-92 
in the spinal cord of STZ-induced type 1 diabetic rats with PDN 
 
A key role for KCC2 in spinal abnormal pain processing during PDN has been suggested 
in different studies (Jolivalt et al., 2008; Lee-Kubli & Calcutt, 2014; C. Morgado, P. Pereira-
Terra, et al., 2011; C. Morgado, P. Pereira‐Terra, et al., 2011; Morgado et al., 2008). 
Although all of these studies have reported decreased levels of KCC2 in the spinal cord of 
STZ-diabetic rats with PDN compared to healthy animals, the mechanisms behind it are still 
elusive. However, in vitro studies using primary cultures of cerebellar granule (Barbato et 
al., 2010) and hippocampal (Vetere et al., 2014) neurons from healthy rodents demonstrated 
an inverse relationship between the levels of KCC2 and miR-92. We, therefore, hypothesized 
that the decrease in the levels of KCC2 observed in the spinal cord of STZ-diabetic rats with 
PDN could be mediated by increases in the levels of miR-92. In order to test our hypothesis, 
we evaluated the levels of miR-92 and KCC2 mRNA in L4-L5 spinal cord samples from 
healthy and STZ-diabetic rats by RT-PCR analysis (Figure 8). 
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Figure 8 – Experimental design of Study 1: Evaluation of the expression levels of KCC2 mRNA and miR-92 in 
the spinal cord of STZ-induced type 1 diabetic rats with PDN. (A) Experimental groups. (B) Timeline. 
 
1.1 Study 1 Results 
 
1.1.1 Blood glucose concentration and body weights 
 
In order to monitor metabolic parameters characteristic of this rat model of type 1 
diabetes, glycaemia and body weights were assessed 4 weeks after STZ injection. We 
verified that STZ-diabetic rats presented increased blood glucose levels and decreased body 
weight compared to control animals (Figures 9 and 10, respectively). 
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Figure 9 – Blood glucose levels of STZ-induced diabetic rats. Average 
blood glucose levels of control (CTR) (n= 8) and STZ-diabetic (STZ) (n= 
9) rats 4 weeks after diabetes induction. Error bars represent SEM.Unpaired 
t test, ****p<0,0001. 
 
 
Figure 10 – Effect of STZ-induced diabetes on body weight. Average 
body weights of control (CTR) (n= 8) and STZ-diabetic (STZ) (n= 9) rats 4 
weeks after diabetes induction. Error bars represent SEM. Unpaired t test, 
****p<0,0001. 
 
1.1.2 Spinal cord miR-92 and KCC2 mRNA expression levels 
 
For miR-92 expression levels analysis, two RT-PCRs were independently made, each 
using different STZ-diabetic and CTR animals. Both assays revealed significant increased 
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expression of miR-92 in the spinal cord of STZ-diabetic rats when compared with healthy 
control animals (Figure 11)  
 
The levels of KCC2 mRNA expression were analyzed and compared in L4-L5 spinal 
cord segments of CTR and STZ-diabetic rats. No changes in KCC2 mRNA expression levels 
were detected between both groups of animals (Figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Effect of STZ-induced diabetes on spinal cord miR-92 expression levels. RT-PCR quantification 
of miR-92 expression levels in the L4-L5 spinal cord segment of control (CTR) and STZ-diabetic (STZ) rats. On 
the left graph, the results of the first experiment using four CTR and four STZ animals are shown. On the right 
graph, the results of the second experiment using further four CTR and four STZ animals are shown. Error bars 
represent SEM. Unpaired t test, *p<0,05.  
 
 
Figure 12 – Effect of STZ-induced diabetes on the spinal cord KCC2 mRNA 
expression levels. RT-PCR quantification of KCC2 mRNA expression in the L4-
L5 spinal cord segment of control (CTR) (n=4) and STZ-diabetic (STZ) (n=4) 
group. Error bars represent SEM. Unpaired t test, non-significant (ns). 
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Our results suggest that increased levels of miR-92 in the spinal cord of STZ-diabetic rats with 
PDN may, indeed, mediate the decreases in KCC2 (at the protein level) observed in these animals 
(C. Morgado, P. Pereira-Terra, et al., 2011; C. Morgado, P. Pereira‐Terra, et al., 2011; Morgado et 
al., 2008). 
 
  
Unraveling the role of microRNA-92 in Painful Diabetic Neuropathy 
30 
 
2. Study 2: Evaluation of the therapeutic potential of the selective inhibition 
of miR-92 in the spinal cord of STZ-induced type 1 diabetic rats with PDN 
 
Given the results of Study 1, supporting a possible role for miR-92 in PDN through spinal cord 
KCC2 levels modulation, we considered important to evaluate the therapeutic potential of a selective 
inhibition of miR-92 in this condition. Our approach was based on that of a recent study in mice by 
Vetere and colleagues (Vetere et al., 2014) in which the selective inhibition of miR-92, using a mir-
92 sponge lentiviral vector, was shown to prevent decreases in KCC2 hippocampal expression and 
alter memory formation process. Briefly, we intraspinally administered a lentiviral vector to restrain 
miR-92—pLSyn miR-92 sponge—to STZ-diabetic rats, while STZ-diabetic sham controls were 
administered pLSyn vector only. To evaluate whether inhibition of miR-92 is able to modulate the 
mechanical hypersensitivity exhibited by this animal model of type 1 diabetes (Morgado et al., 2008; 
Morgado, Silva, Pereira-Terra, & Tavares, 2011) through increases in spinal cord KCC2 levels, all 
animals were behaviorally evaluated for mechanical nociception using the Randall-Selitto test and 
the levels of KCC2 in their spinal cords were analyzed by Western blotting (Figure 13). 
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Figure 13 – Experimental design of Study 2: Evaluation of the therapeutic potential of the selective inhibition of 
miR-92 in the spinal cord of STZ-induced type 1 diabetic rats with PDN. (A) Experimental groups. (B) Timeline. 
 
2.1 Results 
 
2.1.1 Blood glucose concentration and body weights 
 
As in Study 1, all animals were monitored and assessed for glycaemia and body weights 
during the experiment. At day fourteen after lentiviral particles inoculation, STZ-diabetic 
rats presented high blood glucose concentration, which did not differ between STZ-diabetic 
rats inoculated with pLSyn or pLSyn-miR-92 sponge lentiviral particles (Figure 14). 
Similarly, body weights were not significantly different between both groups (Figure 15). 
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Figure 14 – Blood glucose levels of STZ-diabetic rats after intraspinal 
lentiviral particles inoculation. Average blood glucose levels of STZ 
pLSyn (n=13) and STZ pLSyn miR-92 sponge (n=12) rats at 14 days after 
intraspinal inoculations. Error bars represent SEM. Unpaired t test, non-
significant (ns). 
 
 
Figure 15 – Body weights of STZ-diabetic rats after intraspinal lentiviral 
particles inoculation. Average body weights of STZ pLSyn (n= 13) and 
STZ-pLSyn miR-92 sponge (n= 12) rats 14 days after intraspinal 
inoculations. Error bars represent SEM. Unpaired t test, non-significant (ns). 
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2.1.2 Mechanical nociception of STZ rats intraspinally inoculated with pLSyn and 
pLSyn-miR-92 sponge lentiviral particles 
 
Mechanical nociception was evaluated using the Randall-Selitto paw-pressure test 
(PPT) in STZ-diabetic rats before (2 weeks post-STZ injection), and 7 and 14 days after 
pLSyn or pLSyn-miR-92 sponge lentiviral particles intraspinal inoculation. 
Two weeks after the induction of diabetes (before the inoculation of the lentiviral 
particles), our STZ-diabetic rats presented PWT values that are similar to those reported for 
this rat model of type 1 diabetes upon the development of diabetes-induced hyperalgesia 
(Carla Morgado et al., 2011). Fourteen days (14D) after the inoculation of pLSyn miR-92 
sponge, STZ-diabetic animals exhibited a significant increase in the PWTs compared with 
the PWTs observed in the pre-inoculation test. Regarding STZ-diabetic rats inoculated only 
with pLSyn, we observed a decrease in their PWTs after lentiviral particles inoculation 
compared with the PWTs obtained pre-inoculation, although the results did not reach 
statistical significance. Further, STZ rats inoculated with pLSyn-miR-92 sponge presented 
increased PWTs both at day seven (7D) and at day fourteen (14D) after inoculation when 
compared with STZ rats inoculated with pLSyn only. At day fourteen, the difference in 
mechanical nociception between the two groups was more pronounced (Figure 16). 
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Figure 16 – Effect of intraspinal inoculation of pLSyn control and pLSyn miR-92 sponge lentiviral 
particles on the mechanical nociception of STZ-diabetic rats with PDN. Paw withdrawal thresholds 
(PWTs) of STZ-diabetic rats before (Pre-inoculation) 2 weeks after diabetes induction (Pre-inoculation)—at 
week 2 of diabetes, and 7 (7D) and 14 days (14 D) after intraspinal inoculation of pLSyn (n=10) control 
lentiviral particles and pLSyn miR-92 (n=11) lentiviral particles evaluated by the Randall-Selitto paw pressure 
test. Error bars represent SEM. Two-Way ANOVA repeated measures, * corresponds to the comparison 
between STZ pLSyn miR-92 and STZ pLSyn, *p<0,05, **p<0,01, # corresponds to the comparison between 
STZ-pLSyn miR-92 sponge with respective pre-inoculation, ## p<0,01. 
 
2.1.3 Locomotor activity of STZ rats intraspinally inoculated with pLSyn and pLSyn 
miR-92 sponge lentiviral particles 
 
The Open Field test (OFT) was used for the evaluation of locomotor activity of STZ 
spinally inoculated rats in order to assess whether locomotion was affected by the surgery. 
This evaluation is critical since possible locomotion disturbances caused by the intraspinal 
injection procedure can bias the results of the mechanical nociception test. No significant 
differences were detected between the STZ rats inoculated with pLSyn or pLSyn-miR-92 
sponge lentiviral particles (Figure 17). 
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Figure 17 – Analysis of locomotor activity of inoculated STZ-diabetic 
rats after intraspinal surgery. OFT analysis at 14 days after intraspinal 
injection of STZ pLSyn (n=10) and STZ pLSyn miR-92 sponge (n=11). 
Travelled distance in cm was calculated. Error bars represent SEM. Unpaired 
t test, non-significant (ns). 
 
2.1.4 Spinal cord EGFP protein expression levels 
 
All inoculated animals expressed EGFP as detected by Western blotting, showing that 
spinal neurons were transfected by lentiviral particles and the contained transgene was 
transcribed. No significant differences were detected in EGFP expression between the two 
groups of animals (Figure 18).  
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Figure 18 – Quantification of EGFP expressed in the spinal cord of STZ-diabetic rats inoculated with pLSyn and 
pLSyn miR-2 sponge lentiviral particles. Expression levels of EGFP of STZ pLSyn (n=4) and STZ pLSyn miR-92 
sponge (n=4) by Western blotting. Error bars represent SEM. Unpaired t test, non-significant (ns). -, STZ pLSyn, +, 
STZ pLSyn miR-92 sponge. 
 
2.1.5 Spinal cord KCC2 protein expression levels 
 
To verify whether decreased mechanical sensitivity exhibited by STZ-diabetic rats 
administered pLSyn miR-92 sponge lentiviral vector as compared to their counterparts that 
were administered pLSyn was accompanied by increased spinal cord KCC2 levels, the 
expression of this co-transporter was quantified in L4-L5 spinal cord segments by Western 
blotting analysis. The results show that spinal cord of KCC2 protein levels were increased in 
STZ rats that receive an intraspinal inoculation of pLSyn-miR-92 sponge lentiviral particles 
when compared with STZ rats inoculated with pLSyn (Figure 19). 
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Figure 19 – Effect of viral inoculations on spinal cord KCC2 protein expression levels of STZ-diabetic rats. 
Expression levels of KCC2 in the spinal cord of STZ pLSyn (n=4) and STZ pLSyn miR-92 sponge (n=4) by Western 
Blotting. Error bars represent SEM. Unpaired t test, *p<0,05. -, STZ pLSyn, +, STZ pLSyn miR-92 sponge. 
 
 In summary, the results of this study show that in a rat model of STZ-induced type 1 diabetes 
with PDN, STZ-diabetic animals subjected to selective inhibition of spinal cord miR-92 through 
intraspinal injection of a miR-92 sponge lentiviral vector exhibited increased levels of spinal cord 
KCC2 protein and decreased mechanical nociception when compared to STZ animals subjected to 
intraspinal of a control lentiviral vector. Therefore, our results suggest that this procedure of 
selectively inhibiting spinal cord miR-92 may be regarded as a potential therapeutic strategy in PDN. 
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3. Study 3: Assessment of the effects of a KCC2 inhibitor and a 𝐆𝐀𝐁𝐀𝐀R 
antagonist on mechanical nociception of STZ-diabetic rats inoculated 
with pLSyn miR-92 sponge lentiviral particles 
 
To confirm the role of KCC2 as a mediator of the actions of miR-92 inhibition in the 
analgesia observed in STZ-diabetic rats inoculated with pLSyn miR-92 sponge, and to exclude 
other possible underlying mechanisms, a proof of concept pharmacological experiment was 
undertaken by blocking KCC2 with an intrathecal injection of a specific inhibitor, DIOA (30µg) 
(Jolivalt et al., 2008). Furthermore, given that GABA has been shown to have an excitatory role 
when KCC2 is down-regulated and, therefore, to play an important role in pain modulation 
(Chamma et al., 2012; Cordero-Erausquin et al., 2005; Coull et al., 2003; Stil et al., 2009), we 
decided to evaluate the role of GABA also as possible mediator of the actions of miR-92 
inhibition in the decreased nociception observed in STZ.diabetic rats inoculated with pLSyn 
miR-92 sponge. For this evaluation, a pharmacological study was undertaken by intrathecally 
injecting these animals with a GABAA receptor antagonist (which competes with GABA by 
binding A receptors), bicuculline, (BIC) (0,6µg). Briefly, as illustrated in Figure 20 and 
following a methodology based on that described by Jolivalt et al (Jolivalt et al., 2008), three 
weeks after STZ-diabetic rats were inoculated with either pLSyn and pLSyn miR-92, they 
received an intrathecal injection of DIOA, BIC, or vehicle solution (saline + 10% DMSO) and, 
after anesthesia recovery, mechanical nociception was evaluated in all animals using the Randall-
Selitto PPT 15, 30, 45 and 60 min post-intrathecal administrations. The PWTs were determined 
as the average of 3 consecutive measures taken at 2-min intervals. In order to minimize the 
number of experimental animals used in this experiment, and given the preliminary nature of the 
study, each animal was intrathecally injected 2 or 3 times with DIOA, BIC, or vehicle, being 
allowed an interval of at least 48h between injections to assure a suitable washout of the previous 
injected drug (Table 1). 
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Figure 20 – Experimental design of Study 3: Assessment of the effects of a KCC2 inhibitor and a 𝐆𝐀𝐁𝐀𝐀R 
antagonist on mechanical nociception of STZ-diabetic rats inoculated with pLSyn miR-92 sponge lentiviral 
particles. (A) Experimental groups. (B) Timeline. 
 
 
Table 1 - Scheme of intrathecal injections on each animal. 
 Injection Day 
Animal 
Group 
Animal number day 1 day 2 day 3 day 4 day 7 
STZ pLSyn 
6 
 
Vehicle 
 
DIOA  
9 DIOA BIC  
12 DIOA BIC Vehicle 
19 BIC Vehicle  
20 DIOA  Vehicle  BIC 
STZ pLSyn 
miR-92 
sponge 
22 
 
Vehicle 
 
DIOA  
24 DIOA BIC  
23  DIOA  BIC Vehicle 
28 BIC 
 
Vehicle 
 
 
26 DIOA Vehicle BIC 
Vehicle: Saline + 10%DMSO; BIC: Bicuculline; DIOA: [(dihydroindenyl)oxy] 
alkanoic acid 
acid 
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3.1 Study 3 Results 
 
3.1.1 Blood glucose concentration and body weights 
 
As in Study 2, all animals presented high blood glucose concentration, which did not 
differ between STZ rats inoculated with pLSyn or pLSyn-miR-92 sponge lentiviral particles 
(Figure 21). Also, body weights were not significantly different between both groups (Figure 
22). 
 
Figure 21 – Blood glucose levels of STZ-diabetic rats after intraspinal 
lentiviral particles inoculation. Average blood glucose levels of STZ pLSyn 
(n=6) and STZ pLSyn miR-92 sponge (n=7) rats 14 days after intraspinal 
inoculations. Error bars represent SEM. Unpaired t test, non-significant (ns).  
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Figure 22 – Body weights of STZ-diabetic rats after intraspinal 
lentiviral particles inoculation. Average body weights of STZ pLSyn (n= 
6) and STZ-pLSyn miR-92 sponge (n= 7) rats 14 days after intraspinal 
inoculations. Error bars represent SEM. Unpaired t test, non-significant 
(ns). 
3.1.2 Locomotor activity of STZ rats intraspinally inoculated with pLSyn and pLSyn 
miR-92 sponge lentiviral particles 
 
As in Study 2, all animals were tested using the OFT to evaluate their locomotor activity. 
Again, there were no differences in their mobility after surgery, when comparing STZ pLSyn 
and STZ pLSyn miR-92 sponge rats (Figure 23). 
 
Figure 23 – Analysis of locomotor activity of inoculated STZ-diabetic rats 
after intraspinal surgery. OFT analysis 14 days after intraspinal injection of 
STZ pLSyn (n=6) and STZ pLSyn miR-92 sponge (n=7). Travelled distance in 
cm was calculated. Error bars represent SEM. Unpaired t test, non-significant 
(ns). 
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3.1.3 Effects of intrathecal administration of DIOA on the mechanical nociception of 
STZ rats inoculated with pLSyn or pLSyn-miR-92 sponge lentiviral particles 
 
As shown in Figure 24, 30 min after the intrathecal injection of DIOA in STZ-diabetic 
rats inoculated with pLSyn-miR-92 sponge lentiviral particles, these animals presented 
decreased PWTs, i.e. increased mechanical nociception, when compared with the PWTs 
recorded at baseline (before DIOA administration). Further, these animals exhibited 
decreased PWTs 30 and 45 min after DIOA injection compared with their STZ pLSyn miR-
92 counterparts that receive an intrathecal injection with vehicle solution only. Moreover, 
after DIOA injection, the PWTs of STZ pLSyn miR-92 rats did not differ from the PWTs 
exhibited by STZ rats inoculated with pLSyn alone and intrathecally injected with either 
DIOA or vehicle solution. Regarding the results of the intrathecal injection of DIOA in STZ-
diabetic rats inoculated with pLSyn lentiviral particles, we observed that DIOA induced no 
effects on the PWTs of these animals (Figure 24). 
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Figure 24 – Effect of KCC2 inhibitor, DIOA, on mechanical nociception of inoculated STZ-diabetic rats. 
STZ rats inoculated with pLSyn or pLSyn miR-92, injected with vehicle and DIOA were tested by the Randall-
Selitto PPT. PWTs were recorded at 14 days after spinal lentiviral inoculation (Baseline), at 15’, 30’, 45’ and 
60’ aft after intrathecal injection of vehicle or drug. Error bars represent SEM. Two-Way RM ANOVA, * 
corresponds to the comparison between both vehicle groups, *p<0,05, **p<0,01, ****p<0,001, # corresponds 
to the comparison between STZ pLSyn miR-92 Vehicle and STZ pLSyn miR-92 DIOA, #p<0,05, $ 
corresponds to the comparison between STZ pLSyn miR-92 DIOA with STZ pLSyn Vehicle and STZ pLSyn 
DIOA, $p<0,05, & corresponds to the comparison between STZ pLSyn miR-92 DIOA and respective baseline, 
&p<0,05. 
 
3.1.4 Effects of intrathecal administration of BIC on the mechanical nociception of 
STZ rats inoculated with pLSyn or pLSyn-miR-92 sponge lentiviral particles 
 
As can be seen in Figure 25, 30 min after the intrathecal injection of BIC in STZ-diabetic 
rats inoculated with pLSyn-miR-92 sponge lentiviral particles, these animals presented 
decreased PWTs, i.e. increased mechanical nociception, when compared with the PWTs 
recorded at baseline (before BIC administration). Further, these animals exhibited decreased 
PWTs 30 and 45 min after BIC injection compared with their STZ pLSyn miR-92 sponge 
counterparts that received an intrathecal injection of vehicle solution only. Furthermore, after 
BIC injection, the PWTs of STZ pLSyn miR-92 rats did not differ from the PWTs exhibited 
by STZ rats inoculated with pLSyn control lentiviral particles and intrathecally injected with 
vehicle solution. As to the results of the intrathecal injection of BIC in STZ-diabetic rats 
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inoculated with pLSyn control lentiviral particles, we observed that, 45 min post-BIC 
injection, these animals exhibited increased PWTs, i.e. decreased mechanical nociception, 
when compared with the PWTs recorded at baseline (before BIC administration). At this 
time point, STZ pLSyn rats injected intrathecally with BIC presented increased PWTs 
compared with STZ pLSyn rats that received an injection of vehicle solution only. 
 
Figure 25 – Effect of 𝐆𝐀𝐁𝐀𝐀𝐑 antagonist, BIC, on mechanical nociception of inoculated STZ-diabetic 
rats. STZ rats inoculated with pLSyn or pLSyn miR-92, injected with vehicle or BIC, were tested by the 
Randall-Selitto PPT. PWTs were recorded at 14 days after spinal lentiviral inoculation (Baseline), at 15’, 30’, 
445’ and 60’ after intrathecal injection of vehicle or BIC. Error bars represent SEM. Two-Way RM ANOVA, 
* corresponds to the comparison between both vehicle groups, *p<0,05, **p<0,01, ****p<0,0001, # 
corresponds to the comparison between STZ pLSyn miR-92 Vehicle and STZ pLSyn miR-92 BIC, #<0,05, $ 
corresponds to the comparison between STZ pLSyn miR-92 BIC with STZ pLSyn Vehicle and STZ pLSyn 
BIC, $p<0,05, & corresponds to the comparison between STZ pLSyn miR-92 DIOA and respective baseline, 
&&p<0,01, % corresponds to the comparison between STZ pLSyn BIC with STZ pLSyn Vehicle and with 
respective baseline, % p<0,05. 
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4. Study 4: Effects of pro-inflammatory cytokines, TNF-α and IL-1β, on 
KCC2 expression in neuronal cultures (on-going experiments) 
 
Microglia seems to be involved in PDN-induced KCC2 dysregulation, as the inhibition of its 
activity, achieved by an intrathecal administration of minocycline, a specific microglia inhibitor, 
restored spinal KCC2 expression and reversed mechanical hypersensitivity in STZ-diabetic rats 
(C. Morgado, P. Pereira-Terra, et al., 2011). The mechanisms by which microglia inhibition 
reverses these diabetic-induced changes are still elusive. Microglia-secreted brain-derived 
neurotrophic factor (BDNF) was shown to be involved in KCC2 deregulation in other chronic 
pain conditions (Coull et al., 2003), but not involved in PDN (C. Morgado, P. Pereira-Terra, et 
al., 2011; Wardle & Poo, 2003). Interestingly, minocycline was shown to decrease IL-1β and 
TNF-α levels in the spinal cord of STZ-diabetic rats, which were shown to be significantly 
upregulated (Cata, Weng, & Dougherty, 2008; Lee et al., 2003; C. Morgado, P. Pereira-Terra, et 
al., 2011). These findings raised the hypothesis that the reduction in IL-1β and TNF-α may be 
mediating the minocycline effects on spinal KCC2 expression in STZ-diabetic rats. However, 
the involvement of IL-1β and TNF-α in neuronal KCC2 expression was never addressed. 
In order to understand if inflammation affects this cross talk between KCC2-miR-92, 
preliminary tests were made. Neuronal cultures from hippocampus and spinal cord were 
transfected with pro-inflammatory cytokines, and KCC2 protein levels were evaluated as well as 
miR-92 expression in hippocampal neurons (Figure 26). Since there are studies where GABA 
and KCC2 were related (Dai & Ma, 2014; Li, Li, Wei, Qu, & Wu, 2010; Morales-Aza, 
Chillingworth, Payne, & Donaldson, 2004; C. Morgado, P. Pereira-Terra, et al., 2011; Wardle & 
Poo, 2003; Z. Zhang, Wang, Wang, Lu, & Pan, 2013), the follow experiments were a pilot to 
understand which mechanism is underlying modulation of KCC2 and consequently GABA 
reversal. 
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Figure 26 – Experimental design of Study 4: Effects of pro-inflammatory cytokines, TNF-α and IL-1β, on 
KCC2 expression in neuronal cultures (on-going experiments). (A) Experimental groups. (B) Timeline. 
 
4.1 Study 4 Results 
 
4.1.1 Effects of TNF-α and IL-1β in the of KCC2 mRNA and miR-92 in neuronal 
cultures 
 
The expression of KCC2 mRNA and miR-92 was analyzed on hippocampal neuronal 
cultures after 24 hours of exposure to TNF-α and IL-1β. Both inflammatory mediators 
induced a significant decrease in the expression of KCC2 mRNA (Figure 27). No differences 
were detected in the expression of miR-92 (Figure 28). 
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Figure 27 – Effects of TNF-α and IL-1β on KCC2 mRNA expression in 
hippocampal primary cultures. RT-PCR quantification of KCC2 mRNA 
expression levels, in hippocampal neurons cultured in normal medium (CTR) 
(n=3), in medium with the pro-inflammatory cytokine TNF-α (50ng/mL) 
(n=3), and in medium with the pro-inflammatory cytokine IL-1β (10 ng/mL) 
(n=3). Error bars represent SEM. One-Way ANOVA, n=3, * p<0,05, 
**p<0,01. 
 
 
Figure 28 – Effects of TNF-α and IL-1β on miR-92 expression in 
hippocampal primary culture. RT-PCR quantification of miR-92 expression 
levels, in hippocampal neurons cultured in normal medium (CTR) (n=1), in 
medium with the pro-inflammatory cytokine TNF-α (50 ng/mL) (n=1), and in 
medium with the pro-inflammatory cytokine IL-1β (10 ng/mL) (n=1). No 
statistical analysis was made due to insufficient number of cultures. 
 
4.1.2 KCC2 protein expression levels 
 
The expression of KCC2 was evaluated in hippocampal and spinal cord neurons in the 
same pro-inflammatory conditions. In both neurons, the exposure to TNF-α and IL-1β tended 
to decrease KCC2 expression, although no statistical significant differences were reached 
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when compared with controls. The effects tended to be more pronounced in hippocampal 
than in spinal cord neurons (Figure 29 and 30, respectively). 
 
Figure 29 – Effects of TNF-α and IL-1β on KCC2 protein expression levels in hippocampal 
primary cultures. Expression levels of KCC2 protein in hippocampal neurons cultured in 
normal medium (CTR) (n=2), in medium with the pro-inflammatory cytokine TNF-α (50 ng/mL) 
(n=2), and in medium with the pro-inflammatory cytokine IL-1β (10 ng/mL) (n=2), by Western 
Blotting. No statistical analysis was made due to insufficient number of cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 – Effects of TNF-α and IL-1β on KCC2 protein expression levels in spinal 
cord primary cultures. Expression levels of KCC2 protein in spinal cord neurons cultured 
in normal medium (CTR) (n=3), in medium with the pro-inflammatory cytokine TNF-α (50 
ng/mL) (n=3), and in medium with the pro-inflammatory cytokine IL-1β (10 ng/mL) (n=3), 
by Western Blotting. Error bars represent SEM. One-Way ANOVA, non-significant (ns). 
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V. Discussion 
 
In the present study we show, for the first time, that STZ-induced type 1 diabetic rats with PDN 
exhibit increased levels of miR-92 in the spinal cord L4-L5 segment compared with control animals. 
This result supports our hypothesis that the decreases in the levels of KCC2 protein observed in the 
spinal cord of different models of STZ-diabetic rats with PDN (Jolivalt et al., 2008; Lee-Kubli & 
Calcutt, 2014; C. Morgado, P. Pereira-Terra, et al., 2011; C. Morgado, P. Pereira‐Terra, et al., 2011; 
Morgado et al., 2008) could be mediated by increases in the levels of miR-92. However, analysis of 
spinal cord KCC2 mRNA levels revealed no differences between STZ-diabetic and control rats. This 
came as an unexpected result since a study using a computational prediction-based studies approach 
showed that miR-92 has KCC2 mRNA as a target and, using cultures of cerebellar granule neurons, 
it showed that miR-92 directly modulates KCC2 protein expression (Barbato et al., 2010). Thus, our 
results suggest that, in PDN, miR-92 modulation of spinal cord KCC2 protein appears to involve 
mechanisms other than modulation of KCC2 mRNA. It is possible that miR-2 acts on other targets 
that may indirectly influence KCC2 protein levels. Such targets may be proteins involved in potential 
translational and post-translational mechanisms. So far, further to miR-92’s association with KCC2, 
there are only a few studies describing other targets of miR-92, all related with tumorigenesis and 
the apoptotic pathway, such as the pro-apoptotic protein Bim (Al-Nakhle et al., 2010; Niu et al., 
2012; Tsuchida et al., 2011; Ventura et al., 2008).  
This study also shows that in STZ-diabetic rats with PDN, the selective inhibition of miR-92, by 
intraspinal injection of a miR-92 sponge lentiviral vectors (Barbato et al., 2010) increases the levels 
of KCC2 protein compared with STZ-diabetic animals that were not subjected to this miR-92 
inhibition protocol. This result, besides confirming a role for spinal cord miR-92 in the regulation of 
KCC2 protein, further supports the effectiveness of the use of pLSyn miR-92 sponge lentiviral 
particles developed by Barbato and colleagues (Barbato et al., 2010; Vetere et al., 2014) in inhibiting 
actions previously demonstrated in the mouse hippocampus (Vetere et al., 2014). Moreover, we show 
that by inhibiting miR-92 in the spinal cord of STZ-diabetic rats, it was possible increase their 
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mechanical nociceptive thresholds when compared to STZ animals subjected to intraspinal injection 
of a control lentiviral vector only, suggesting that this procedure is able to decrease pain perception 
and could, therefore, be regarded as a potential future therapeutic strategy for pain relief in PDN and, 
perhaps, other painful disorders. 
Considering that spinal cord KCC2 levels have a major role in the shift of GABA action, from 
inhibitory to excitatory, and that this change may be responsible for increased pain sensitivity in 
STZ-diabetic rats (Jolivalt et al., 2008; Morgado et al., 2008), a pharmacological study was 
undertaken in order to verify and further understand the crosstalk between KCC2 and GABA as 
possible mediators of the analgesic action of miR-92 inhibition. In normal conditions, KCC2 
maintain cells’ homeostasis extruding chloride and, consequently, modulating GABA effect to 
inhibitory (Fiumelli, Cancedda, & Poo, 2005; Rivera et al., 1999). In STZ-diabetic rats with PDN, it 
was shown that the opposite occurs, i.e. GABA effect is excitatory, due to decreases in spinal cord 
KCC2 levels (Morgado et al., 2008). In our study, the effects of miR-92 inhibition on pain responses 
to noxious mechanical stimulation were shown to be dependent on spinal KCC2 actions, as the 
intrathecal injection of DIOA, a specific KCC2 inhibitor, was shown to revert the analgesia induced 
by the inoculation of pLSyn-miR92 sponge lentiviral particles in the STZ-diabetic animals. 
Unexpectedly, injection of DIOA on STZ-diabetic rats inoculated with pLSyn had no effect on their 
PWTs, which may be due to possible limitations of the Randall-Selitto PPT and, therefore, it is 
critical to test this experiment with other mechanical nociception and tactile allodynia tests. 
Moreover, the inoculation of pLSyn-miR-92 sponge lentiviral particles in the STZ-diabetic animals 
was shown to restore the inhibitory post-synaptic role of GABA, as the intrathecal administration of 
BIC, a GABAAR antagonist, was shown to decrease the PWTs in these animals. On the contrary, 
BIC administration in STZ rats inoculated with pLSyn elicited an analgesic effect, showing that the 
post-synaptic role of GABA was excitatory and hyperalgesic in such condition. These findings 
corroborate the results from previous studies (Jolivalt et al., 2008), showing an analgesic effect of 
BIC in STZ rats and reinforce the role of KCC2 expression in the shift of GABA action from 
inhibition to excitation in spinal nociceptive neurotransmission in type 1 diabetic rats. The results of 
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this study allow us to conclude that decreased mechanical nociception exhibited by STZ-diabetic 
animals intraspinally inoculated with pLSyn miR-92 sponge lentiviral particles when compared to 
STZ animals inoculated with a control lentiviral vector is, indeed, mediated by increased KCC2 
levels which, in turn, cause a shift in the action of GABA from excitatory to inhibitory. 
The mechanisms leading to KCC2 deregulation during PDN are still not well understood. It is 
known that microglia activation contributes to KCC2 neuronal disruption in the spinal cord of 
diabetic rats with PDN (Daulhac et al., 2006; C. Morgado, P. Pereira-Terra, et al., 2011; Pabreja, 
Dua, Sharma, Padi, & Kulkarni, 2011; Talbot & Couture, 2012; Tsuda, Inoue, & Salter, 2005; Tsuda, 
Ueno, Kataoka, Tozaki‐Saitoh, & Inoue, 2008; Wang, Couture, & Hong, 2014; Wodarski, Clark, 
Grist, Marchand, & Malcangio, 2009), although the mechanisms behind microglia contribution are 
still unknown. Our findings showed that KCC2 mRNA levels were significantly decreased in 
hippocampal neurons exposed to the pro-inflammatory cytokines, TNF-α and IL-1β, but only a 
tendency for a reduction was detected in KCC2 protein expression in the same experiments. It is 
important to stress that that KCC2 protein levels experiment is not conclusive given its preliminary 
nature (n=2). However, if confirmed, this result may be related to the time needed for KCC2 
recycling at the plasma membrane. More precisely, while significant differences in KCC2 mRNA 
were already present 24h after IL-1β or TNF-α exposure, the effects on protein expression may occur 
latter or need a higher period of exposure to the pro-inflammatory mediators to occur. This lack of 
significant differences in KCC2 protein expression was also observed using the same experimental 
protocol in spinal cord neuronal cultures. It remains to evaluate if KCC2 mRNA expression is also 
affected by IL-1β and TNF-α in spinal cord neurons. In a single experiment we tested if miR-92 
expression was altered by the exposure of hippocampal neurons to IL-1β and TNF-α. This very 
preliminary result indicated a slight reduction, which needs to be confirmed in future studies. 
The completion of these in vitro studies may provide important clues on the possible role of 
inflammation on the disruption of spinal cord miR-92 and KCC2 levels in PDN.  
In conclusion, this study strongly supports a role for miR-92 in the regulation of KCC2, 
providing new insights on the ethiopathology of PDN and opening new perspectives on novel 
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therapeutic approaches. Moreover, our results are of interest for the study and treatment of other 
neurological disorders associated with KCC2 disruption such as other chronic pain conditions and 
epilepsy (Dai & Ma, 2014; Palma et al., 2006; Rivera et al., 2002; Woo et al., 2002). 
. 
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ATTACHMENTS 
 
Recipes 
 
1. Phosphate buffered saline (PBS) (1 L): 
PB 0.4 M pH=7.2 – 250 mL 
NaCl – 9 g 
H2O up to 1L 
 
2. Tris-Glycine-SDS (TGS 1X) (500mL): 
Tris-glycine – 50 mL 
SDS 0,1% – 5 mL 
H2O up to 500 mL 
 
3. Tris-Glycine (TG) 1X with 20% Methanol (500mL): 
Tris-glycine – 50 mL 
Methanol – 100 mL 
 
4. Phosphate buffered saline with Triton X-100 (PBS-T) (1 L): 
PBS – 900 mL 
Triton X – 100 mL 
 
5. Phosphate buffered saline with Tween 20 (PBS/T) (1 L): 
PBS-T 25X – 20 mL 
Tween 20 – 500 µL 
H2O up to 1L 
 
6. Transfer buffer (10X) (1 L): 
Glycine – 29.3 g 
Tris base – 58.15 g 
10% SDS – 37.5 mL 
H2O up to 1L 
 
7. Transfer Buffer with 20% Methanol (1 L): 
Transfer buffer 10X – 100 mL 
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Methanol – 200 mL 
H2O up to 1L 
 
8. Tissues – 4x SDS-PAGE sample buffer: 
240 mM Tris/HCl pH 6.8 
40% glycerol 
8% SDS 
0.04% bromophenol blue – tiny bit 
10% β-Mercaptoethanol – added just before protein sample use 
 
9. Tissues – Lysis buffer: 
20 M MOPS, pH 7.0; 
2 mM EGTA; 
5 mM EDTA; 
1% Triton X-100 
1% Phosphatase inhibitor cocktail 2 (Sigma-Aldrich, St. Louis, MO) 
1% Phosphatase inhibitor cocktail 3 (Sigma-Aldrich, St. Louis, MO) 
1% Proteases inhibitor (Sigma-Aldrich, St. Louis, MO) 
 
10. Cell culture – 2X Laemmli loading buffer: 
125 mM tris-HCL pH6.8 
4% SDS 
20% glycerol 
0,04% bromophenol blue – tiny bit 
10% β-Mercaptoethanol – added just before protein sample use 
 
11. Cell culture – Lysis buffer: 
1% Triton 
0,25% SDS 
1% Sodium Deoxycholate 
2mM EDTA 
1mM DTT 
Fresh phosphatase and protease inhibitors 
 
12. Ponceau solution (1X): 
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Ponceau – 0.2 % 
Trichloroacetic acid – 3 % 
Sulphosalicylic acid – 3% 
 
Western-Blotting Protocol for Tissues: 
 
1. Preparation of samples homogenates: 
- Dissect the tissue of interest and quickly transfer to dry ice to prevent tissue degradation; 
- Store samples at -80°C for posterior use or keep on ice for immediate homogenization; 
- For a ~200 mg of tissue, add ~1000 μl lysis buffer rapidly to the tube, homogenize with ~75% 
of lysis buffer with a mechanical homogenizer, rinse one time with the remainder lysis buffer; 
- Incubate on ice about 20 min; 
- Centrifuge for 20 min at 21100xg at 4 ºC; 
- Transfer the supernatant to a fresh tube kept on ice and discard the pellet; 
- Centrifuge again for 10 min at 21100xg at 4 ºC and collect the supernatant to another tube; 
- Store the homogenates at -80 ºC. 
 
2. Sample preparation: 
- Remove a small volume of lysate to perform a protein assay using the standard protocol of 
Bradford to determine the protein concentration; Bovine serum albumin (BSA) should be used 
as the protein standard; 
- Add to final protein concentration, 1X Sodium Dodecyl Sulphate (SDS) sample buffer, 
distilled H2O and β-Mercaptoethanol 
- Boil each tissue homogenate with sample buffer at 100 ºC for 5 min; 
- Store homogenates at -20 ºC until use; 
- In the moment of use, homogenates should be rapidly defrosted at 37°C and centrifuge at 
max speed in a microcentrifuge; 
 
3. Determination of the Protein Concentration: 
-Prepare protein standard in buffer ranging from 0 –1.5 mg/ml using a BSA standard; 
- In 96 well plate, add 5 μl of homogenate, previously thawed; 
- Add 250 μl of Bradford reagent in each well and mix gently for 30 seconds; 
- Let the samples incubate at room temperature for 5–45 min; 
- Measure the absorbance at 595 nm; 
- Plot the net absorbance vs. the protein concentration of each standard; 
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- Determine the protein concentration of the unknown samples by comparing the A595 values 
against the standard curve. 
 
4. SDS-PAGE and electrophoresis 
- Prepare the resolving gel (8%) (1 gel) 
Acrylamide (40%) – 1,5 mL 
Gel buffer – 1,875 mL 
H2O d – 4,125 mL 
SDS 10% – 75 μL 
TEMED – 3,75 μl 
APS (10%) – 75 μl 
- Prepare the stacking gel (6%) (1 gel): 
Acrylamide (40%) – 563 μL 
Gel buffer – 938 μL 
H2O – 2,063 mL 
SDS 10% – 37,5 μL 
TEMED – 3 μl 
APS (10%) – 75 μl 
- Load equal amounts of protein into each well of the SDS-PAGE gel. Load of 40 μg of total 
protein from each samples; 
- Electrophoresis is performed during 1 to 2 hours at 20 mA; 
 
5. Protein transfer to nitrocellulose membranes: 
- Immerse sponges, filter papers and nitrocellulose membranes in 1X transfer buffer with 20% 
methanol; 
- Prepare the transfer stack as follows: 
(+) sponge - filter paper - nitrocellulose membrane - gel - filter paper - sponge (-) 
- Transfer the protein, by electroblotting, at 30 V overnight with stacks totally immersed in 
transfer buffer with 20% methanol; 
- Check protein transfer quality by staining the membranes with Ponceau solution. 
 
6. Immunodetection of specific proteins: 
- Incubate the membranes with primary antibody for 1 overnight at 4 ºC; 
- Rinse with PBS/T; 
- Incubate with secondary antibody with blocking buffer (5% skimmed milk with 
PBS/T) for 1 hour; 
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- Rinse with PBS/T for 30 min (3x10 min); 
- Incubate with Clarity™ Western ECL Substrate (BioRad, Portugal) (two compounds in the 
ratio 1:1) for 5 min; 
- The signal is detected by ChemiDoc XRS + system (BioRad, Portugal). 
 
Cultured cells 
1. Protein Extraction: 
- Add 70 uL of Lysis buffer to each dish (35mm); 
- On ice, wash each dish with PBS 1X twice; 
- Add lysis buffer and scrape. (Save some lysis buffer for quantitation); 
- Collect to in a new tube and incubate for 30 min on ice; 
- Store at -80ºC. 
- To have a complete cell lysis, make some “freeze and thaw” cycles: thaw on ice, centrifuge 
at 12000xg for 20 min at 4ºC, collect to in a new tube, put at -80ºC for 20-30 min. Repeat until 
the lysate is clear and liquid (not gluey). 
2. Determination of Protein Concentration: 
- Prepare protein standard in buffer ranging from 0 –1 mg/ml using a BSA standard 
(10mg/mL); 
- Prepare solution A’: 20 uL reagent S/ 1mL reagent A. 
- DC Assay – Standards: 100 uL standard + 100 uL solution A’ + 800 uL solution B 
- DC Assay – Samples: 98 uL H20 + 2 uL Sample + 100 uL solution A’ + 800 uL solution B. 
Samples in duplicate 
- Read samples absorbance on Biospectophotometer. 
 
RT-PCR Protocol: 
1. RNA extraction: 
- Always on ice, remove growth media; 
- Wash with PBS; 
-  On the hood, add 1mL of TRIzol in the cells. Lyse the cells directly in the culture dish by 
pipetting up and down several times; 
- Continue RNA isolation procedure according to TRIzol Reagent manufacturing instructions. 
 
2. DNAse Treatment: 
- DNAse treatment and removal reagents according to TURBO DNA-free Kit manufacturing 
instructions. 
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3. Reverse Transcription and RT-PCR: 
- For mRNA, perform reverse transcription according to SYBR Green Kit manufacturer’s 
instructions. 
- For microRNA, perform reverse transcription according to TaqMan Kit manufacturer’s 
instructions. 
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